JY
LPCN icon

Jeff Yass’s Lipocine LPCN Stock Holding History

Jeff Yass’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-87,100
Closed -$240K – 12831
2023
Q4 		$240K Sell
87,100
-100
-0.1% -$265 ﹤0.01% 10307
2023
Q3 		$256K Hold
87,200
– – ﹤0.01% 9691
2023
Q2 		$436K Buy
87,200
+81,976
+1,569% +$386K ﹤0.01% 8630
2023
Q1 		$28.4K Sell
5,224
-16,694
-76% -$129K ﹤0.01% 11934
2022
Q4 		$149K Sell
21,918
-135
-0.6% -$984 ﹤0.01% 10497
2022
Q3 		$169K Sell
22,053
-2,265
-9% -$25.3K ﹤0.01% 11081
2022
Q2 		$331K Sell
24,318
-6,129
-20% -$95.5K ﹤0.01% 9311
2022
Q1 		$709K Buy
30,447
+15,212
+100% +$318K ﹤0.01% 8049
2021
Q4 		$256K Sell
15,235
-6,977
-31% -$130K ﹤0.01% 10864
2021
Q3 		$412K Sell
22,212
-9,888
-31% -$218K ﹤0.01% 9857
2021
Q2 		$764K Sell
32,100
-11,412
-26% -$268K ﹤0.01% 8504
2021
Q1 		$1.12M Buy
43,512
+37,724
+652% +$1.09M ﹤0.01% 7453
2020
Q4 		$134K Sell
5,788
-18,471
-76% -$445K ﹤0.01% 10321
2020
Q3 		$581K Buy
+24,259
New +$644K ﹤0.01% 7367
2018
Q1 		– Sell
-2,924
Closed -$171K – 9801
2017
Q4 		$171K Buy
2,924
+2,218
+314% +$138K ﹤0.01% 8404
2017
Q3 		$48K Sell
706
-2,106
-75% -$152K ﹤0.01% 8547
2017
Q2 		$192K Buy
2,812
+1,394
+98% +$90.9K ﹤0.01% 8326
2017
Q1 		$94K Buy
1,418
+671
+90% +$43.5K ﹤0.01% 8416
2016
Q4 		$47K Sell
747
-412
-36% -$26.1K ﹤0.01% 9301
2016
Q3 		$88K Sell
1,159
-5,253
-82% -$325K ﹤0.01% 7987
2016
Q2 		$331K Buy
6,412
+5,506
+608% +$853K ﹤0.01% 6795
2016
Q1 		$156K Buy
906
+65
+8% +$11.1K ﹤0.01% 8180
2015
Q4 		$185K Buy
+841
New +$176K ﹤0.01% 8491

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jeff Yass's LPCN Position: Q2 2026 in Review

Jeff Yass increased its Lipocine (LPCN) stake by 1.9% in Q2 2026, buying an estimated $1.13K and bringing the position to 25,376 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #12733.

Jeff Yass first reported a position in LPCN in Q4 2015 and has held it in 32 quarters since. The position peaked at $700K in Q1 2016. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • Jeff Yass held 25,376 shares of Lipocine worth $65K as of Q2 2026.
  • Jeff Yass bought 468 Lipocine shares in Q2 2026, an estimated $1.13K.
  • Lipocine made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12733 holding.
  • Jeff Yass first reported a position in Lipocine in Q4 2015 and has held it in 32 quarters since.
  • Jeff Yass's Lipocine position peaked at $700K in Q1 2016.
  • 36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.